Taysha Gene Therapies Inc (TSHA) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Taysha Gene Therapies Inc stock $2.30, price $4.06, that is 43.3% below the price, quality 32 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Taysha Gene Therapies Inc
TSHA · USFar too expensive (fair value 43% below the price), weak company and price moving sideways: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $0.5900 – $21.57 · fair‑value band $1.72 – $2.87 · the $4.06 price screens above the $2.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Taysha Gene Therapies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
Show moreShow less
The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Stock analysis
Taysha Gene Therapies Inc (TSHA) currently trades at $4.06, while our estimate is $2.30, 43% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.72 (bear) to $2.87 (bull), the price of $4.06 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Taysha Gene Therapies Inc reported revenue of $9.8M in FY2025 versus $0 in FY2021. Reported net income was −$109M in FY2025.
Key figures
Market cap $1.5B Small · EPS (TTM) $−0.4200 · Return on equity −54.2% · Return on assets (EBIT) −62.4% (5-year average) · Operating margin −2,998% · Revenue (TTM) $5.5M · Revenue growth (YoY) +171% · Free cash flow −$93.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 42% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −43%, TSHA screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director sold shares worth $1.2M and none bought.
- SaleSukumar NagendranPresident and Head of R&D, Director5× since Nov 28, 2025: 1,086,222 shares, avg. $4.90$5.3MJul 10, 2026
- SaleKamran AlamCHIEF FINANCIAL OFFICER2× since Jan 23, 2026: 104,472 shares, avg. $4.71$492,522Feb 4, 2026
- SaleSean P. NolanChief Executive Officer, Director178,101 shares at $4.72$840,196Jan 26, 2026
Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Taysha Gene Therapies Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs TSHA |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs TSHA |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs TSHA |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs TSHA |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs TSHA |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs TSHA |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs TSHA |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs TSHA |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs TSHA |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs TSHA |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Taysha Gene Therapies Inc (TSHA) overvalued or undervalued?
What is the fair value of TSHA?
What is the quality score of TSHA?
What is the price target for Taysha Gene Therapies Inc (TSHA)?
What is the Taysha Gene Therapies Inc stock forecast for 2026?
What is the revenue of Taysha Gene Therapies Inc (TSHA)?
What is the intrinsic value of Taysha Gene Therapies Inc (TSHA)?
Is Taysha Gene Therapies Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of TSHA?
How much is Taysha Gene Therapies Inc worth?
What do the bullish and bearish scenarios say about TSHA?
How solid is the balance sheet of Taysha Gene Therapies Inc (TSHA)?
How far is TSHA from its 52-week high?
Which stocks are comparable to Taysha Gene Therapies Inc?
Is Taysha Gene Therapies Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Taysha Gene Therapies Inc (TSHA)?
What should I pay attention to with Taysha Gene Therapies Inc right now?
Key figures of Taysha Gene Therapies Inc
How large is the market capitalisation of Taysha Gene Therapies Inc (TSHA)?
What are the earnings per share of Taysha Gene Therapies Inc (TSHA)?
What is the return on equity of Taysha Gene Therapies Inc (TSHA)?
What is the EBIT return on assets of Taysha Gene Therapies Inc (TSHA)?
What is the operating margin of Taysha Gene Therapies Inc (TSHA)?
How fast is revenue growing at Taysha Gene Therapies Inc (TSHA)?
How much free cash flow does Taysha Gene Therapies Inc (TSHA) generate?
How much net cash does Taysha Gene Therapies Inc (TSHA) hold?
Watch Taysha Gene Therapies Inc in the live analysis
One click puts Taysha Gene Therapies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.